SWTX SpringWorks Therapeutics
- 41.200
- +2.340+6.02%
- 42.450
- +1.250+3.03%
SpringWorks Therapeutics News
BofA Securities Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Cuts Target Price to $55
SpringWorks Therapeutics Price Target Lowered to $55 From $58 at BofA
Catalyst Watch: Eyes on Electric Vehicle Deliveries, Retail Data and Housing Reads
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Springworks Therapeutics (SWTX)
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
J.P. Morgan Sticks to Their Buy Rating for Springworks Therapeutics (SWTX)
SpringWorks Therapeutics Initiated at Outperform by Evercore ISI Group
SpringWorks Therapeutics Analyst Ratings
Evercore Initiates SpringWorks Therapeutics(SWTX.US) With Buy Rating, Announces Target Price $60
Express News | SpringWorks Therapeutics Inc : JP Morgan Raises Target Price to $70 From $68
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $58 to $74
Barclays Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)
Buy Rating Reaffirmed for Springworks Therapeutics Amid Promising Outlook for Ogsiveo and Mirdametinib
No Data